Skip to content Skip to navigation

Laura Marquadt


Despite numerous clinical trial attempts, the use of cell-based therapies for treating spinal cord injury have yet to translate into an effective clinical treatment due to poor cell survival and function. Dr. Marquardt's research sought to design an injectable hydrogel platform to overcome these translational limitations. Through recombinant protein engineering and biomaterial design approaches, Dr. Marquardt investigated a material called SHIELD that promotes enhanced transplanted cell retention and function resulting in improved functional recovery after spinal cord injury.